Discovery and Antiviral Profile of New Sulfamoylbenzamide Derivatives as HBV Capsid Assembly Modulators.

[1]  M. Nassal,et al.  The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target , 2021, Biomedicines.

[2]  M. Iannacone,et al.  Immunobiology and pathogenesis of hepatitis B virus infection , 2021, Nature Reviews Immunology.

[3]  Yuchen Xia,et al.  Hepatitis B Virus cccDNA: Formation, Regulation and Therapeutic Potential. , 2020, Antiviral research.

[4]  J. Neefs,et al.  Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro. , 2020, The Journal of antimicrobial chemotherapy.

[5]  W. Kim,et al.  Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time , 2020, Clinical liver disease.

[6]  A. Zlotnick,et al.  Local stabilization of subunit-subunit contacts causes global destabilization of Hepatitis B virus capsids , 2020, bioRxiv.

[7]  F. Zoulim,et al.  Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.

[8]  Joan M. Block,et al.  A global scientific strategy to cure hepatitis B. , 2019, The lancet. Gastroenterology & hepatology.

[9]  D. Liotta,et al.  Recent advances in the development of HBV capsid assembly modulators. , 2019, Current opinion in chemical biology.

[10]  D. Hoffmann,et al.  Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. , 2019, ACS infectious diseases.

[11]  G. Wong,et al.  Unmet need in chronic hepatitis B management , 2019, Clinical and molecular hepatology.

[12]  S. Kuduk,et al.  Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus , 2018, Antimicrobial Agents and Chemotherapy.

[13]  T. Volz,et al.  Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. , 2017, Gastroenterology.

[14]  S. Yan,et al.  Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. , 2017, Journal of medicinal chemistry.

[15]  F. García-Alcalde,et al.  Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms , 2017, Scientific Reports.

[16]  V. Wong,et al.  Infection and Cancer: The Case of Hepatitis B. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Rodrigo Quiroga,et al.  Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening , 2016, PloS one.

[18]  C. Lukacs,et al.  High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein , 2015, Proceedings of the National Academy of Sciences.

[19]  Jiaqian Pan,et al.  Anti-HBV Drugs: Progress, Unmet Needs, and New Hope , 2015, Viruses.

[20]  David Ryan Koes,et al.  Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise , 2013, J. Chem. Inf. Model..

[21]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.